MedTrace Logo

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

NCT02846766 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-08-02

No results posted yet for this study

Summary

This is a two center, open label, non-randomized Phase II study of lenvatinib in adult subjects with recurrent or refractory advanced cancers with aberration(s) in FGF/FGFR signaling. Treatment will consist of daily oral administration of Lenvatinib in 28-day cycles.

Conditions

Interventions

DRUG

Lenvatinib

Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    collaborator INDUSTRY

  • Teresa Helsten, MD

    lead OTHER

Principal Investigators

  • Teresa Helsten, MD · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2020-06-01
Completion
2021-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846766 on ClinicalTrials.gov